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in  SLC2A9 as the cause of RHUC2 in a native Austrian family. 
We show that glucose transporter 9 mutations cause severe 
hypouricemia in homozygous individuals and confirm the 
high risk of AKI in male individuals harbouring these muta-
tions. In our literature review, we provide an overview of the 
putative underlying pathophysiology, potential renal com-
plications, findings on kidney biopsy as well as potential 
long-time renal sequelae.  © 2016 S. Karger AG, Basel 
 Introduction 
 Hereditary renal hypouricemia (RHUC) is a geneti-
cally heterogenous disorder caused by recessive muta-
tions in genes encoding distinct urate transporters in the 
proximal renal tubule. The resultant defective urate reab-
sorption causes increased urate clearance with very low 
serum uric acid (UA) levels (<2 mg/dl)  [1] . While affect-
ed individuals frequently remain asymptomatic, a predis-
position for nephrolithiasis and acute kidney injury 
(AKI), often following exercise, has been recognized.
 Mutations in 2 genes account for virtually all reported 
cases, with notable exceptions  [2, 3] . In a majority of pa-
tients, the defect is caused by loss-of function mutations 
in the  SLC22A12 gene that codes for the urate transport-
er URAT1 (RHUC1). In addition, familial hypouricemia 
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 Abstract 
 Background: Hereditary renal hypouricemia (RHUC) is a ge-
netically heterogenous disorder characterized by defective 
uric acid (UA) reabsorption resulting in hypouricemia and 
increased fractional excretion of UA; acute kidney injury 
(AKI) and nephrolithiasis are recognized complications. Type 
1 (RHUC1) is caused by mutations in the  SLC22A12 gene, 
whereas RHUC2 is caused by mutations in the  SLC2A9 gene. 
Patient ethnicity is diverse but only few Caucasian families 
with an  SLC2A9 mutation have been reported.  Methods: The 
current report describes the clinical history, biochemical and 
molecular genetics findings of a native Austrian family with 
RHUC2. The propositus presented with 2 episodes of exer-
cise-induced AKI and exhibited profound hypouricemia. Mu-
tational screening of the  SLC22A12 and  SLC2A9 genes was 
performed.  Results: The molecular analyses revealed the ho-
mozygous c.512G>A transition that leads to the p.Arg171His 
missense substitution in  SLC2A9 , confirming the diagnosis of 
RHUC2. Segregation study of the causal mutation revealed 
that the mother and elder sister were heterozygous carriers, 
whereas the younger sister was found to be homozygous. 
 Conclusion: We report the identification of a novel mutation 
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has also been described in patients harbouring homozy-
gous or compound heterozygous mutations in the 
 SLC2A9 gene, which encodes another key player in UA 
homeostasis, glucose transporter 9 (GLUT9; RHUC2). 
Patient ethnicity is diverse and includes Japanese, 
 Chinese,  Arab, Ashkenazi-Jewish, Anglo-Saxon, Greek, 
and Czech; to date, only few Caucasian families with a 
GLUT9 mutation have been reported  [4–7] .
 We describe a young native Austrian man who expe-
rienced 2 episodes of exercise-induced AKI, exhibited 
profound hypouricemia with markedly increased frac-
tional excretion (FE) of UA and was found to be homo-
zygous for a novel missense mutation in  SLC2A9 . While 
the mother and elder sister tested heterozygous for the 
mutation, the younger sister carried the mutation in ho-
mozygosity and displayed extremely low serum UA lev-
els; however, she has not experienced any episodes of 
AKI.
 Case Report 
 A previously well 16-year-old Caucasian male was admitted be-
cause of sudden onset of bilateral loin pain, nausea and vomiting. 
There was no history of nephrolithiasis and family history was un-
remarkable. He was on no regular medications and did not smoke 
or use illicit drugs. The previous day, he had engaged in 20 min of 
barbell-training. On admission, the patient was euvolemic, afe-
brile; blood pressure was 144/82 mm Hg and pulse rate 96 beats 
per minute. Apart from mild abdominal tenderness, physical ex-
amination was unremarkable.
 Pertinent laboratory results were as follows: serum creatinine 
2.1 mg/dl, creatine kinase (CK) 1,503 U/l, lactate dehydrogenase 
250 U/l; full blood count was normal. Urinalysis showed trace of 
protein (+) but no cells, casts, haemoglobin or myoglobin; urinary 
pH was 6. Serologic data (anti-nuclear antibody, hepatitis B and C, 
human immunodeficiency virus and complement) were all nor-
mal. Toxicology screen was negative. A renal ultrasound showed 
normal-sized kidneys with no evidence of obstruction. Within 
3 days, serum creatinine peaked at 4.4 mg/dl, while CK normal-
ized. UA, which was not done initially, was 1.1 mg/dl at that time. 
A kidney biopsy was performed and showed only subtle signs of 
acute tubular injury without intratubular UA precipitation ( fig. 1 a, 
b). Renal function recovered spontaneously and profound hypou-
ricemia (0.2 mg/dl at discharge) became evident. Blood results 
from a previous admission 3 years earlier showed normal serum 
creatinine (0.8 mg/dl) but UA of 0.1 mg/dl. No secondary causes 
of low UA were evident. FE-UA was very high (126%, normal 
range 7–12%) in the acute phase.
 In view of the marked hypouricemia and high FE-UA, a diag-
nosis of RHUC was suspected, which led us to perform mutation-
al screening of the  SLC22A12 and  SLC2A9 genes, as previously 
described  [8] . The molecular analyses revealed the homozygous 
c.512G>A transition (seq. ref.: NM_020041.2) that leads to the p.
Arg171His missense substitution (GLUT9L, seq. ref.: NP_064425.2) 
in  SLC2A9 , thus confirming the diagnosis of the RHUC type 2 
( fig. 2 ). Interestingly, the Arg171 residue has been previously re-
ported by Dinour et al.  [9] to be substituted by a Cys residue in 
3  siblings, born of consanguineous Israeli-Arab parents, with 
RHUC2 and without complications. In vitro functional expression 
studies showed that the p.Arg171Cys mutant protein had signifi-
cantly reduced UA transport activity (16% of control values). Fur-
thermore, homology modelling indicated that the mutation oc-
curred in the inner channel that expels UA from the cytoplasmic 
to extracellular regions  [9] .
 The serum UA levels were screened in other family members 
and were 2.7 mg/dl (mother), 2.7 mg/dl (elder sister) and 
0.1 mg/ dl (younger sister); FE-UA was 22, 14.2 and >150%, re-
spectively. The father could not be contacted. Segregation study 
of the causal mutation, performed for all available relatives, re-
vealed that the mother and elder sister were heterozygous carri-
ers ( fig. 2 ), whereas the younger sister was found to be homozy-
a b
 Fig. 1. Renal biopsy showing mild signs of acute tubular injury with tubular ectasia with flattening of epithelia 
cells (focal interstitial oedema) with very few scattered interstitial inflammatory cells, no casts or precipitations 
within tubuli (and no glomerular lesions):  a periodic acid-Schiff;  b trichrome acidic fuchsin orange-G. 
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gous, in agreement with her very low UA levels. However, de-
spite an active lifestyle, at the age of 24, she remained 
asymptomatic until this date.
 In contrast, and 9 months after his initial presentation, the in-
dex patient was readmitted with abdominal pain and myalgia of 
the upper arms. The previous day, he had moved furniture for sev-
eral hours. At presentation, only 1 day after the onset of symptoms, 
his serum creatinine was 3.9 mg/dl. Again, no structural abnor-
malities were detected on renal ultrasound. Urinary dipstick 
showed protein (quantified at 0.8 g at that time) but no haemoglo-
binuria; urinary pH was 6. No UA crystals were found under urine 
microscopy. Kidney function and proteinuria normalized sponta-
neously. On follow-up, UA remained between 0.1 and 0.2 mg/dl 
and FE-UA was calculated repeatedly >150%. By avoidance of 
strenuous exercise no further episode of exercise-induced AKI has 
occurred to date.
 The presence of a novel mutation in homozygosity is suggestive 
of consanguinity, though the family pedigree could not be defined 
with certainty.
 Discussion 
 In humans, urate is the end product in purine metabo-
lism and it exerts important oxidative defence. Its serum 
concentration is governed by hepatic production and 
predominantly renal removal. Urate is filtered freely by 
the glomerulus and is almost completely reabsorbed in 
the proximal tubule; consequently, the kidney plays a 
dominant role in maintaining serum urate levels  [1] .
 Hypouricemia is arbitrarily defined as a serum urate 
concentration of <2 mg/dl. While it can result from de-
creased UA production, it is usually due to renal urate 
wasting  [4] . Following Erley’s description in 1989 of a 
young Turkish man who experienced exercise-induced 
AKI requiring transient dialysis and was later found to be 
profoundly hypouricemic, it became evident that RHUC 
constitutes not just a mere biochemical curiosity  [10] . 
The ensuing years saw an increasing number of reports of 
RHUC patients presenting with acute kidney failure  [11] . 
However, the underlying molecular defect remained ob-
scure until Enomoto et al.  [12] reported the identification 
of the first kidney specific urate transporter URAT1 
 (SLC22A12) in 2002. Inactivating mutations in this gene 
have been subsequently found in individuals with idio-
pathic RHUC and >100 patients have been described, the 
majority being Japanese  [13] . However, the existence of 
RHUC patients without URAT1 mutations implied the 
presence of additional major urate regulators  [1] .
 In 2007, GLUT9 (encoded by  SLC2A9 ) was identified 
as another high capacity urate transporter  [14] . GLUT 
G T G G G A AC G C CCT T T G T G G G A AC R C CCT T T G T G G G A AC A C CCT T T
140 1 140 140 1
Control Carrier Patient
 Fig. 2. Molecular characterization. Sequence chromatogram show-
ing the position of the novel c.512G>A transition (NM_020041.2, 
GLUT9L) that corresponds to c.425G>A (NM_00100290.1, 
GLUT9S), leading to the p.Arg171His missense mutation 
(NP_064425.2, GLUT9L) and to p.Arg142His (NP_001001290.1, 
GLUT9S). The mutation was found in homozygosity in the index 
patient and his younger sister and in heterozygosity in his mother 
and elder sister; the father was not available for genetic testing. 
Mutations are annotated according to HGVS nomenclature 
(http://www.hgvs.org/mutnomen). 
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proteins are encoded by the SLC2 genes and mediate the 
transport of monosaccharides and other small carbon 
compounds across cell membranes. To date, 14 GLUT 
proteins have been identified, but GLUT9 represents the 
only member of this family whose substrate is urate. Its 
2 variants – long (GLUT9L) and short (GLUT9S) – act in 
tandem with URAT1 in renal reabsorption of UA  [15] . 
While urate uptake from the tubular lumen into the cell is 
mediated by URAT1 and by apical GLUT9S, GLUT9L is 
the only major urate efflux transporter at the basolateral 
membrane. Hence, loss of function of GLUT9 precludes 
UA reabsorption by all of the apical transporters through 
complete inhibition of UA efflux from the cell  [9] .
 Shortly thereafter, mutations in  SLC2A9 were de-
scribed in hypouricemic patients, rendering  SLC2A9 an-
other causative gene linked to RHUC  [16] . When com-
pared to patients with URAT1 mutations, individuals 
harbouring homozygous GLUT9 mutations exhibit more 
pronounced hypouricemia with FE-UA often >150%, 
and appear to be more vulnerable for exercise-induced 
AKI and nephrolithiasis  [13, 16] . Subjects with heterozy-
gous GLUT9 mutations show a wider spectrum of serum 
UA levels, ranging from 2.0 to 4.5 mg/dl, whereas FE-UA 
values range from 3.2 to 21.7% in one study from Israel 
 [16] ; these authors concluded that haploinsufficiency re-
sults in mild hypouricemia. The recent report of a 54-year-
old Czech woman with a novel heterozygous missense 
mutation in the  SLC2A9 gene, exhibiting low serum UA 
levels (1.16–1.78 mg/dl) and FE-UA of 17.7%, is in line 
with this observation; functional study of the identified 
mutation showed a significant decrease in urate uptake 
 [7] . We have previously summarized the molecular and 
clinical features of all RHUC2 patients reported until 
2014  [8] , and only a few new cases were published in the 
meanwhile  [6, 7, 17, 18] .
 Several mechanisms have been proposed to explain the 
pathophysiology of AKI in RHUC. Although Erley’s de-
scription demonstrated urate nephropathy as the histo-
logical correlate of acute renal failure, further reports did 
not substantiate this finding  [19] ; indeed, a majority of 
renal biopsies has shown acute tubular injury without in-
tratubular UA precipitation  [20] . However, luminal mi-
crocrystals will not be inevitably evident on histology. As 
discussed in our previous report, the UA precipitation 
hypothesis proposes that prolonged or severe exercise can 
be associated with an elevation in UA production and uri-
nary excretion  [8] . If this condition is associated with hy-
povolemia, increased urine concentration and low urine 
pH, it favours the precipitation and crystallization of UA. 
Notably, a recent paper on ‘heat stress nephropathy’ dis-
cusses the potential detrimental effects of cyclic, exercise-
induced uricosuria in the pathogenesis of Mesoamerican 
nephropathy. The authors show that high concentrations 
of noncrystalline UA per se, potentiated by volume deple-
tion and urinary acidification in the course of exercise, 
cause renal tubular injury  [21] . This concept could also 
apply to RHUC patients.
 While the precise mechanism for kidney injury re-
mains elusive, the role of UA as an antioxidant has in-
creasingly garnered attention. Murakami et al.  [22] were 
the first to suggest that oxygen-free radicals produced 
during exercise lead to renal tissue damage. Total serum 
UA and the amount mobilized into the tubular cells are 
very small in RHUC patients, resulting in insufficient an-
tioxidant action in the renal cortex. As oxidative stress 
increases during exercise, renovascular spasm may ensue 
and reperfusion after exercise mimics ischemia-reperfu-
sion injury  [23] . The histological finding of interlobular 
artery intimal thickening in a normotensive RHUC2 pa-
tient, attributed to repeated vasoconstriction, renders 
further support to this pathophysiological concept, which 
is also backed by CT findings showing patchy wedge-
shaped enhancement in renal parenchyma  [18, 24] . Inter-
estingly, evidence for a more systemic oxidant imbalance 
at presentation with AKI accumulates: 3 cases of poste-
rior reversible encephalopathy syndrome have been re-
cently reported in RHUC1 and RHUC2 patients, and one 
Japanese RHUC1 individual exhibited reversible T-wave 
inversion on ECG; together, these reports are suggestive 
of cerebral and coronary artery constriction, respectively 
 [19, 24–26] . That being said, other disorders associated 
with hypouricemia, such as hereditary xanthinuria, are 
not usually associated with AKI. Moreover, RHUC pa-
tients can remain asymptomatic throughout their life, as 
exemplified by an 84-year-old subject with a homozygous 
 SLC2A9 mutation  [9] . We have previously speculated 
that additional genetic risk factors, for instance, sequence 
variations in other urate transporters, and various envi-
ronmental triggers, may contribute to the development of 
complications  [8] . Lastly, expression of URAT1 and 
GLUT9 is not confined to the kidney: while URAT1 is 
expressed by vascular smooth muscle cells, GLUT9 is also 
found in the brain  [25, 27] . We hypothesize that this sys-
temic distribution might account for the non-renal com-
plications of RHUC.
 The presentation follows a remarkably stereotypical 
pattern. After various forms of exercise (occasionally triv-
ial activities such as house cleaning)  [20] , loin pain, nau-
sea and vomiting develop. The short time lag between ex-
ercise and symptom onset in the presentation is notewor-
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thy and in keeping with reversible vasoconstriction rather 
than urate nephropathy. While moderate CK elevation is 
commonly found, frank rhabdomyolysis is unusual.
 The marked male preponderance for exercise-related 
AKI, with a male:female ratio of 8: 1 in one study, has been 
noted before and is found consistently in the literature  [8, 
11, 21] . Gender-related differences in oxidative stress, at-
tributed to estradiol, might account for this phenomenon 
 [23] .
 Previous laboratory examinations, when available, 
may assist in RHUC diagnosis. While complex urine ex-
amination was commonly performed in patients with hy-
pouricemia before the characterization of the major urate 
transporters, suggestive biochemistry and family history 
should prompt early molecular analysis of the 2 known 
causative genes, as illustrated by our reports.
 Patients should be counselled to avoid strenuous exer-
cise and ensure adequate fluid intake after exercise. Rath-
er counterintuitively, allopurinol, a potent inhibitor of 
xanthine oxidase, may have a role in preventing recurrent 
episodes  [3] . While this basically fits with the ‘cyclic uri-
cosuria’-hypothesis, (high-dose) allopurinol has also 
been shown to improve endothelial function by reducing 
vascular oxidative stress, perhaps unrelated to its effect on 
UA  [28] . In the metabolism of xanthine to UA, free radi-
cals are generated; it is conceivable, therefore, that allo-
purinol exerts its effect as a powerful antioxidant.
 Although some patients require interim dialysis, the 
short-term prognosis of RHUC appears to be favourable. 
However, recurrence of AKI has been described and there 
is evidence that repeated kidney injury can cause chronic 
structural alterations  [18, 20] ; end-stage renal disease in 
RHUC patients has been reported  [29] . Furthermore, a 
recent large cross-sectional population-based study from 
Japan demonstrated that men with hypouricemia face a 
higher risk of reduced kidney function  [30] .
 As stipulated by Stiburkova et al.  [13] , lack of aware-
ness of RHUC likely allows cases to go undetected. In-
deed, patients have been subjected to repeat renal biop-
sies when hypouricemia was not noticed at first presenta-
tion  [17] .
 To summarize, we report the identification of a novel 
mutation in  SLC2A9 as the cause of RHUC2 in a native 
Austrian family. In analogy with previous reports, we 
show that GLUT9 mutations cause severe hypouricemia 
in homozygous individuals and confirm the high risk of 
AKI in male individuals harbouring these mutations.
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